Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | S100B | P04271 | 1/20 | 0.32 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10072632 | 0.92 | ESR1 (0.33) | ESR1S100BRPS6KA2LMNAHTT | |
| SCHEMBL19121257 | 0.78 | S100B (0.39) | S100BLMNAMAPTGFER | |
| SCHEMBL8295729 | 0.75 | L3MBTL1 (0.43) | HTTMAPTCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL29518050 | 0.71 | S100B (0.34) | S100BLMNA | |
| SCHEMBL655093 | 0.71 | S100B (0.52) | S100BLMNAMAPTCYP1A2GFER | |
| SCHEMBL653573 | 0.70 | MAPT (0.40) | LMNAHTTMAPTCYP1A2CYP2C19 | |
| SCHEMBL19198529 | 0.70 | CYP3A4 (0.36) | ESR1CYP1A2CYP2C19 | |
| SCHEMBL20160730 | 0.69 | ESR1 (0.35) | ESR1MAPTCYP1A2CYP2C19 | |
| SCHEMBL8295758 | 0.68 | L3MBTL1 (0.43) | HTTMAPTCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL21208575 | 0.68 | S1PR1 (0.38) | S100BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119680-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8017629-B2 | Compounds and uses thereof in modulating amyloid β | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100331551-A1 | ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM | NEUROGENETIC PHARMACEUTICALS, INC | 2010-12-30 | — | — | US | disclosed |
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-7799808-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7781442-B2 | Compounds and uses thereof in modulating amyloid beta | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | TORREYPINES THERAPEUTICS INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | TORREYPINES THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | APP, BACE1, BACE2 | ESR1 4698/4885S100B 32/4885RPS6KA2 3131/4885 |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | APP, BACE1, BACE2 | ESR1 4698/4885S100B 32/4885RPS6KA2 3131/4885 |
| US-20100331551-A1 | ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM | HYPK, APP, NEFM | ESR1 4704/4885S100B 1476/4885RPS6KA2 295/4885 |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | PSEN2, APP, BACE1 | ESR1 3182/4885S100B 212/4885RPS6KA2 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.